Blueshift Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Blueshift Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$367K	Buy	+14,832	New	+$353K	0.11%	285
2022 Q2	–	Sell	-10,941	Closed	-$91K	–	736
2022 Q1	$91K	Buy	+10,941	New	+$77.3K	0.01%	772
2020 Q1	–	Sell	-56,554	Closed	-$212K	–	288
2019 Q4	$212K	Buy	+56,554	New	+$264K	0.02%	705

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Blueshift Asset Management's CPRX Position: Q1 2026 in Review

Blueshift Asset Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 14,832 shares worth $367K. The stake represents 0.11% of the portfolio and ranks #285 among its holdings. This is a return to the name: Blueshift Asset Management previously reported a position in CPRX as recently as Q1 2022.

Blueshift Asset Management first reported a position in CPRX in Q4 2019 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Blueshift Asset Management held 14,832 shares of Catalyst Pharmaceutical worth $367K as of Q1 2026.
Catalyst Pharmaceutical was a new Blueshift Asset Management position in Q1 2026.
Catalyst Pharmaceutical made up 0.11% of Blueshift Asset Management's portfolio in Q1 2026, its #285 holding.
Blueshift Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2019 and has held it in 3 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Blueshift Asset Management's 13F filing for Q1 2026, filed 14 May 2026.